Back to top
more

bluebird bio (BLUE)

(Delayed Data from NSDQ)

$0.92 USD

0.92
5,160,078

+0.01 (1.13%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $0.93 +0.01 (0.78%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How

by Zacks Equity Research

bluebird bio (BLUE) rises 25.6% in past thirty days on upbeat earnings results and promising progress with its approved therapies.

bluebird (BLUE) Q3 Earnings Top; Zynteglo, Skysona Fuel Sales

by Zacks Equity Research

bluebird bio (BLUE) reports better-than-expected results in the third quarter of 2023 due to product revenues now being generated from Skysona (elivaldogene autotemcel) and Zynteglo (betibeglogene autotemcel).

AstraZeneca (AZN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga, are likely to have driven sales in the third quarter, partially offset by lower sales of legacy drugs.

Ginkgo (DNA) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Ginkgo's (DNA) third-quarter earnings call, investor focus is likely to be on the sales performance of its two business units ¿¿¿ Biosecurity and Cell Engineering.

Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Catalyst's (CPRX) third-quarter 2023 earnings are expected to have been driven by the robust performances of its two marketed drugs, Firdapse and Fycompa CIII.

Biogen (BIIB) to Report Q3 Earnings: Will It Beat Estimates?

by Zacks Equity Research

Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.

Novo Nordisk (NVO) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Novo Nordisk (NVO) is likely to outperform third-quarter 2023 estimates, driven by increased Diabetes and Obesity Care product sales despite severe rivalry and pricing pressure in the United States.

Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vertex (VRTX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Vertex (VRTX) is likely to outperform third-quarter 2023 estimates, driven by the increased international sales of its lead drug, Trikafta/Kaftrio.

Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of Zoetis' (ZTS) companion animal and livestock products are expected to have driven sales in the third quarter of 2023, partially offset by declining swine product sales.

Femasys (FEMY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Femasys' (FEMY) revenues in third-quarter 2023 are expected to have been driven by the higher international sales of its marketed products. Pipeline updates are expected over the earnings call.

Eton Pharma (ETON) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Eton Pharma's (ETON) revenues in the third quarter of 2023 are expected to have been driven by the sales of its marketed products.

2seventy bio (TSVT) to Cut Jobs & Expand JW Therapeutics Deal

by Zacks Equity Research

2seventy bio (TSVT) undertakes a restructuring program and announces plans to reduce 40% of its workforce. The company also plans to expand its collaboration with JW Therapeutics.

Bluebird (BLUE) Up 7.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

bluebird's (BLUE) Lovo-cel to Not Face Advisory Committee

by Zacks Equity Research

bluebird (BLUE) announces that its gene therapy, lovotibeglogene autotemcel, developed for sickle cell disease, will not be scheduled for advisory committee meeting, thereby accelerating the path for approval.

Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More

by Zacks Equity Research

Regulatory updates from Galecto (GLTO) and Sonnet BioTherapeutics Holdings (SONN) are in focus in the biotech sector.

bluebird (BLUE) Q2 Earnings Top, Zynteglo & Skysona Fuel Revenues

by Zacks Equity Research

bluebird bio (BLUE) reports better-than-expected results in the second quarter of 2023 due to product revenues now being generated from Skysona (elivaldogene autotemcel) and Zynteglo (betibeglogene autotemcel).

Bluebird Bio (BLUE) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Bluebird (BLUE) delivered earnings and revenue surprises of 6.94% and 25.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.

Kinjel Shah headshot

Drug, Biotech Stocks' Q2 Earnings on Aug 8: LLY, LGND & More

by Kinjel Shah

Let us look at five drug/biotech companies, LLY, LGND, NVAX, EBS and BLUE, which are gearing up for their earnings release.

Novo Nordisk (NVO) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Novo Nordisk's (NVO) Diabetes and Obesity Care products are expected to have boosted sales in the second quarter of 2023 amid severe competition and pricing pressure in the United States.

CRISPR (CRSP) to Post Q2 Earnings: What's in the Offing?

by Zacks Equity Research

CRISPR (CRSP) currently does not have any marketed product in its portfolio. The company is expected to provide regulatory updates on exa-cel applications, along with other pipeline updates.

Ligand (LGND) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Ligand's (LGND) second-quarter 2023 performance is likely to have been driven by rising royalty revenues on the back of higher growth in sales of drugs developed using its pelican platform.

NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 0% and 42.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of Zoetis' (ZTS) companion animal and livestock products are expected to have driven sales in second-quarter 2023, partially offset by lower sales of swine products.